News | January 06, 2010

ACNM, SNM to Hold Joint Nuclear Medicine Conference

January 6, 2010 - The American College of Nuclear Medicine (ACNM) is holding its annual meeting Jan. 27-28, 2010, in Albuquerque, N.M., in conjunction with the Society of Nuclear Medicine's (SNM) Mid-Winter Meeting.

The meeting, which provides attendees with the opportunity to earn up to 25 continuing education credits, will highlight the latest advancements in molecular imaging and nuclear medicine. The educational sessions will conclude with special workshops on nanomedicine and clinical trials.

The ACNM meeting will offer presentations on PET/CT of the head and neck, including thyroid cancer, chest and abdomen. ACNM will also offer lectures on the use of molecular imaging for lung scans and brain imaging and the use of new PET radiopharmaceuticals for treating disease. For nuclear medicine and radiology residents, ACNM will offer abstract presentations and a session on how to find a job in nuclear medicine.

SNM will offer a two-day CT case review workshop that will provide 16 hours of continuing education credit for physicians. SNM will also offer workshops on the use of molecular imaging for the diagnosis of neurodegenerative disorders, and diagnosis and treatment of heart failure. Sessions will take place Jan. 29-31.

SNM's Technologist Section (SNMTS) will host "The Sharp Edges of Nuclear Medicine: See What's New," Jan. 30-31,2010, to introduce technologists to new techniques in fusion imaging, with a focus on patients with epilepsy. SNMTS will also host a joint session with the American Society of Radiologic Technologists, focusing on legislative and regulatory issues facing nuclear medicine today, including USP and the Medicare Improvement Providers and Patients Act of 2008 (MIPPA).

SNM's Molecular Imaging Center of Excellence will host its annual summit on Jan. 31 and Feb. 1. This year's summit will focus on nanomedicine and molecular imaging. More than 20 experts from a variety of fields will examine current and potential uses of nanomaterials for patient care through improved diagnosis and individualized treatment strategies.

The week will cap off with SNM's Clinical Trials Workshop (CTN), Feb. 1-2, 2010. The CTN Workshop will expand on last year's successful meeting through in-depth presentations and discussions about how to expedite drug discovery, gain approval for new biomarkers, and comply with regulatory requirements in the U.S. and abroad. Featured seminars will cover the need for standardization in imaging trials, clinical research operating procedures, quality assurance, phantom utilization and good manufacturing practices. The CTN will host a special roundtable on the evening of Feb. 1 for leadership and senior staff at clinical research organizations. The CTN will also host sessions especially for nuclear medicine technologists about professional development opportunities in clinical trials research.

For more information: www.snm.org

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.